©2022 PCMA. All Rights Reserved.
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries
Recent small fluctuations year-to-year in the number of independent pharmacies has not dramatically shifted the independent pharmacy market and continues to foster a stable market.
2023 2022 2021 2020 2019 2018 2017
Lawmakers: Increase Competition In The Prescription Drug Market – Don’t Constrain It. S. 127, the “Pharmacy Benefit Manager Transparency Act of 2023” fundamentally misconstrues the role of pharmacy benefit companies, who are working every day to secure savings, enable better
Rx RESEARCH CORNER The PBM Marketplace is More Competitive, Not Less Rx RESEARCH CORNER The PBM Marketplace is More Competitive, Not Less NEWSROOM New PCMA Ad Campaign: Reject Big Pharma’s Agenda Designed To Keep Drug Prices High By Undermining Pharmacy
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) Chief Policy and External Affairs Officer Kristin Bass released the following statement on the legislative markup on prescription drug pricing legislation by the U.S. Senate Committee on the Judiciary. “We applaud members
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International Convention happening this week in Boston, MA misses the critical opportunity to address the root
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities